Neuroprotection with felbamate: a 7- and 28-day study in transient forebrain ischemia in gerbils.
The use of glutamate antagonists and GABA agonists may protect neurons from the effects of transient ischemia. Felbamate is a new antiepileptic drug with glutamate antagonist and GABA agonist properties. We tested the efficacy of felbamate in a gerbil model of transient forebrain ischemia. Damage assessment was done with silver staining at 7 and 28 days after 5 min of bilateral carotid occlusion. Cerebral cortex, hippocampus (CA1 and CA4), thalamus and striatum were evaluated on a 4-point scoring system. The animals sacrificed at 28 days were also tested in a water-maze task to assess recovery of function. The initial dose of felbamate (300 mg/kg) was given 30 min before the ischemic insult in one set of animals and 30 min after the insult in another set of animals. There were 8 animals tested per group (total: 48 animals). There was significant neuronal protection with the use of felbamate, both before and after ischemia in all regions of the brain. Protection was seen in animals sacrificed at 7 and 28 days. Protection was moderate when felbamate was used before ischemia. It was highly significant when felbamate was given 30 min after the insult. Behavioral studies however did not show any difference in the felbamate treated animals versus the saline treated controls. The structural protection with felbamate was very significant when used in the post-ischemic period. This window for protection merits further evaluation in relation to the clinical setting of stroke.
Shuaib
A
A
Department of Medicine (Neurology), Saskatchewan Stroke Research Center, College of Medicine, University of Saskatchewan, Saskatoon, Canada.
Waqaar
T
T
Ijaz
M S
MS
Kanthan
R
R
Wishart
T
T
Howlett
W
W
D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology; D002339:Carotid Arteries; D002540:Cerebral Cortex / Q000473:pathology; D003342:Corpus Striatum / Q000473:pathology; D000078328:Felbamate; D005849:Gerbillinae; D006624:Hippocampus / Q000473:pathology; D002546:Ischemic Attack, Transient / Q000473:pathology* / Q000503:physiopathology* / Q000517:prevention & control; D008297:Male; D018782:Maze Learning / Q000187:drug effects*; D018696:Neuroprotective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D048448:Phenylcarbamates; D011409:Propylene Glycols / Q000494:pharmacology* / Q000627:therapeutic use; D016548:Prosencephalon / Q000187:drug effects / Q000473:pathology* / Q000503:physiopathology; D012016:Reference Values; D013788:Thalamus / Q000473:pathology; D013997:Time Factors
D000927:Anticonvulsants; D018696:Neuroprotective Agents; D048448:Phenylcarbamates; D011409:Propylene Glycols; D000078328:Felbamate